In this review, we gathered and discussed current studies on the impacts and latent mechanisms of IL-22 in CTDs (i.e., SLE, RA, SS, SSc and DM), aiming to provide new therapeutic targets for CTDs. The gene discussed is IL22; the disease is systemic sclerosis.